HC Wainwright Has Bullish Forecast for NMRA FY2025 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – HC Wainwright increased their FY2025 EPS estimates for Neumora Therapeutics in a research note issued on Sunday, November 9th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($1.47) for the year, up from their prior estimate of ($1.54). The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q4 2025 earnings at ($0.37) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.45) EPS, FY2027 earnings at ($1.50) EPS, FY2028 earnings at ($1.12) EPS and FY2029 earnings at $0.07 EPS.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Thursday, November 6th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01).

A number of other brokerages have also recently commented on NMRA. Mizuho lifted their target price on Neumora Therapeutics from $4.00 to $5.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. JPMorgan Chase & Co. downgraded Neumora Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Tuesday, September 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Wednesday, October 8th. Needham & Company LLC boosted their price objective on shares of Neumora Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Finally, Guggenheim raised shares of Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 target price on the stock in a research note on Monday, October 27th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $7.43.

Neumora Therapeutics Trading Up 4.0%

Shares of NASDAQ NMRA opened at $2.86 on Wednesday. Neumora Therapeutics has a 1-year low of $0.61 and a 1-year high of $11.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.85 and a quick ratio of 6.85. The business’s 50 day moving average is $2.03 and its two-hundred day moving average is $1.48. The stock has a market capitalization of $477.88 million, a P/E ratio of -1.95 and a beta of 2.98.

Hedge Funds Weigh In On Neumora Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. CWM LLC increased its position in shares of Neumora Therapeutics by 7,124.4% during the first quarter. CWM LLC now owns 25,213 shares of the company’s stock worth $25,000 after acquiring an additional 24,864 shares during the period. Jump Financial LLC bought a new position in Neumora Therapeutics in the first quarter worth approximately $25,000. Legacy Private Trust Co. bought a new position in Neumora Therapeutics in the third quarter worth approximately $25,000. Catalyst Funds Management Pty Ltd purchased a new position in Neumora Therapeutics during the 2nd quarter worth $29,000. Finally, Aigen Investment Management LP purchased a new position in Neumora Therapeutics during the 1st quarter worth $36,000. 47.65% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Neumora Therapeutics

In related news, Director Kristina Burow purchased 1,915,700 shares of Neumora Therapeutics stock in a transaction that occurred on Monday, October 27th. The shares were bought at an average price of $2.61 per share, with a total value of $4,999,977.00. Following the purchase, the director directly owned 6,046,907 shares of the company’s stock, valued at approximately $15,782,427.27. This represents a 46.37% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Arch Venture Partners Xii, Llc acquired 1,915,700 shares of the firm’s stock in a transaction that occurred on Monday, October 27th. The shares were bought at an average price of $2.61 per share, with a total value of $4,999,977.00. Following the acquisition, the insider directly owned 6,046,907 shares in the company, valued at $15,782,427.27. This represents a 46.37% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 26.80% of the stock is currently owned by company insiders.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.